Navigation Links
Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Date:6/6/2013

CARLSBAD, Calif., June 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $6 million payment from AstraZeneca related to continuation of the research collaboration between Isis and AstraZeneca to discover and develop novel antisense therapeutics to treat cancer.  In addition to the research collaboration, which includes three cancer targets, Isis and AstraZeneca are developing two antisense drugs, ISIS-ARRx and ISIS-STAT3Rx, discovered by Isis and licensed to AstraZeneca for the treatment of cancer. 

"We are pleased to be working with AstraZeneca, a global leader in oncology, and are already benefiting from our collaborative efforts.  In just six months, we have selected a new development candidate, ISIS-ARRx, to move forward into clinical development to treat patients with prostate cancer and initiated two clinical studies on ISIS-STAT3Rx in patients with advanced lymphomas and liver cancer.  We are also making progress selecting the next three oncology targets that we and AstraZeneca will focus our research efforts toward," said B. Lynne Parshall , chief operating officer at Isis.  "The success of this collaboration is an example of how our partnering strategy enables us to develop a broad pipeline of antisense drugs in a variety of therapeutic areas.  Our oncology franchise consists of five antisense drugs in development to treat patients with a variety of cancers.  We look forward to continuing to expand our cancer franchise with AstraZeneca as we move our research programs forward toward development."

In December 2012, Isis entered into a collaboration with AstraZeneca to discover and develop antisense drugs to treat cancer. The collaboration combines AstraZeneca's experience and
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... agreement with OmniComm to gain more control over the management of ... ... Fla., Nov. 4 OmniComm,Systems, Inc. (OTC Bulletin Board: OMCM.OB), a ... an extensive,evaluation of the leading EDC vendors, the Sarah Cannon Research ...
... BETHESDA, Md., Nov. 4 Micromet, Inc. ... antibodies,for the treatment of cancer, inflammation and ... showing cytotoxic activity of,anti-EpCAM antibody adecatumumab (MT201) ... 1, 2008 at the 23rd Annual meeting ...
Cached Medicine Technology:Sarah Cannon Research Institute Selects OmniComm Systems' Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management 2Sarah Cannon Research Institute Selects OmniComm Systems' Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management 3Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 2Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 3Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 4Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells 5
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian cancer ... think outside the bra. She doesn’t try to hide her ... about women’s other lady parts. , "We have won the ... pink and everybody knows what you’re talking about,” Jess-Huff points ... not been won when it comes to gynecologic cancers. It ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today ... new module enables easy administration and routing of follow-up ... , This application allows users such as Therapists to ... to-do item to a specific client, categorize tasks the ... reminders for follow-ups. It's designed to enable easy ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
(Date:10/20/2014)... 20, 2014 Rockynol Retirement Community ... on Oct. 14. The $11 million project will include ... a cooked-to-order kitchen with full-service restaurant style dining. , ... for first class Assisted Living apartments,” said Kara Hanzie, ... the highest quality of care and this investment is ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... discovered the genetic factors that make some mosquitoes resistant ... the mosquitos immune system is the key to their finding. ... parasite that causes malaria, a biochemical reaction is triggered that ... on to the parasites surface and targeting it for termination, ...
... a teenager Scot of severe asthma. ,Fifteen-year-old ... had to give up sports and physical education lessons at ... had read somewhere about the benefits of playing wind instruments ... one. ,Being a proud Glasgow-born Scot, David ...
... received the world's first face transplant 18 months ago said Friday ... in the mirror with a combination of sadness and wonder. ... have a face, a smile, facial expressions which allow them to ... an interview published in Saturday's edition of Le Monde. ...
... the allegedly substandard Chinese products make constant headlines in the ... crackdown. ,For starters it has suspended the sale ... arthritis. ,In the past week alone, a former ... sentenced to death on bribery charges, and it was announced ...
... in OK! magazine's list of 'most influential' celebrities. ... the 'beauty queen' category for her 'refreshing girl-next-door look' ... Beyonce and Jennifer Lopez behind. ,According to ... celebrities in six categories including beauty queens, style setters, ...
... has openly confessed that she had sex with former boyfriend Justin ... she was married. ,"I've only slept with one person ... relationship with Justin, and I thought he was the one. But ... The most painful thing I have ever experienced was that ...
Cached Medicine News:Health News:Genetic Factors Behind Mosquitoes Resistance to Malaria Identified 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2Health News:China Cracks the Whip Against Drug Manufacturers Who Fail Quality Norms 2
... The CineScan A/B represent a true ... analog image with technology and diagnostic capability ... in the vitreous. Adjust the gain up ... would be invisible at a standard 90db ...
EchoScan US-2500 is available in a single configuration or in combination with the A scan for maximum cost efficiency....
... in the 21st century requires ... Alcon® UltraScan® imaging system responds ... at clinical echographic needs in ... permits step-by-step processing to collect ...
PremierEdge™ MVR Knives. Angled....
Medicine Products: